AIS Healthcare

Based in Texas, US, AIS Healthcare is a pharmaceutical company specializing in advanced healthcare solutions, particularly in infusion care and targeted drug delivery for patients with rare diseases and chronic conditions. AIS Healthcare, founded in 1998 by Chuck Bell, operates from its headquarters in Dallas, Texas. The company focuses on advanced healthcare solutions, particularly in infusion therapy and drug delivery systems. In April 2013, AIS Healthcare received recapitalization from Excellere Partners, although financial terms were not disclosed.

The company has engaged in one total deal since its inception. AIS Healthcare specializes in providing advanced healthcare solutions through its two primary divisions: Advanced Infusion Care (AIC) and Targeted Drug Delivery (TDD). The AIC division focuses on immunoglobulin (Ig) and Alpha-1 therapy, delivering these treatments either in-home or at infusion suites, primarily catering to patients with rare diseases, chronic pain, and immune deficiencies. The TDD division offers patient-specific compounded medications and services for individuals utilizing surgically implanted intrathecal infusion pumps, critical for delivering precise medication.

While the company previously produced products such as NovoTears and OPDrops for specific ophthalmic conditions, production ceased in May 2022. AIS Healthcare serves a diverse client base across various geographical markets, emphasizing patient-centric care and support for providers, primarily in the United States. AIS Healthcare operates on a transactional model that encompasses both direct-to-consumer services and collaborations with healthcare providers. Clients engage with the company through structured partnerships where healthcare professionals prescribe necessary treatments, supported by AIS Healthcare's nursing services for administration and follow-up care.

Revenue is generated through the delivery of immunoglobulin therapies and compounded medications, tailored to individual patient needs, ensuring effective treatment outcomes. The pricing structure reflects the specialized nature of the therapies provided, fostering long-term relationships with healthcare partners and enhancing patient care quality. AIS Healthcare is focused on expanding its market presence and enhancing its product offerings. Although specific upcoming products have not been disclosed, the company is exploring opportunities to launch new therapies in response to patient needs.

The company aims to expand its services into additional geographical markets across the United States by leveraging its established partnerships and innovative healthcare solutions. The recapitalization in April 2013 will be utilized to support these expansion initiatives and product development, although specific financial allocations have not been detailed.